Drug Manufacturers - Major

RECENT NEWS
MarketWatch  2 hrs ago  Comment 
Shares of iBio soared 42% in active premarket trade Thursday, after the company said it has offered to assist the U.S. government by making its proprietary antibody production technology available to deal with the current Ebola virus outbreak. In...
New York Times  Oct 16  Comment 
The $54 billion takeover of the Irish pharmaceutical company Shire appears to be in jeopardy after the Treasury changed tax rules to discourage companies from reincorporating overseas.
StreetInsider.com  Oct 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Insys+Therapeutics+%28INSY%29+Receives+DEA+Approval+to+Produce+Pharmaceutical+Cannabidiol/9914098.html for the full story.
Benzinga  Oct 15  Comment 
West Pharmaceutical Services Inc. (NYSE: WST) fell sharply after it predicted full-year profits below expectations and said its chief executive will retire next year. The Eaton, Pennsylvania-based drug-maker put third-quarter earnings in line...
Wall Street Journal  Oct 15  Comment 
Pharmaceutical giant AbbVie said it was re-evaluating its planned $54 billion acquisition of Shire in light of new U.S. rules making it harder for American companies to lower taxes through overseas deal making.
Wall Street Journal  Oct 14  Comment 
CSL Ltd., Australia’s biggest pharmaceutical company, said it will buy back 950 million Australian dollars (US$827 million) of its own shares over the next year.
Mondo Visione  Oct 14  Comment 
The Securities and Exchange Commission today announced insider trading charges against a Massachusetts man who allegedly tipped his friend with nonpublic information about potential acquisition targets of the pharmaceutical company where he...
SeekingAlpha  Oct 14  Comment 
By Cory Renauer: With its legendary brands an industry leading pharmaceutical pipeline, Johnson & Johnson (NYSE:JNJ) is a defensive portfolio in a single stock. Despite layers of insulation from economic cycles, even the healthcare juggernaut is...
SeekingAlpha  Oct 14  Comment 
By David Schauber, Jr.: Today, Johnson & Johnson (NYSE:JNJ) reported earnings for their third quarter and offered guidance for the rest of 2014. Let's take a look and see how they did, and what we can expect going forward. The Results For...
Wall Street Journal  Oct 14  Comment 
Johnson & Johnson’s third-quarter earnings rose 59% on higher pharmaceutical sales despite a stronger U.S. dollar and a smaller boost from its Olysio hepatitis C drug.




 

The pharmaceutical industry consists of companies that research, develop, market, and distribute drugs for nearly every therapeutic need. Drug sales from the 65 largest pharmaceuticals totaled $606 billion in 2007 and continues to grow.[1]

Commercial drug companies are driven by research and patent protection. Developing a drug requires an enormous amount of investment in technology, materials, and time, and can be a risky venture for the company. However, after a new drug is successfully developed, thoroughly tested, and patented, it may be potentially very lucrative, especially if it addresses a common health problem (such as heart disease or cancer).

Pharmaceutical Industry Trends & Forces

Pipeline Risks

Developing a new drug is a time-consuming and costly endeavor. Hundreds of thousands of candidate compounds must be screened to identify a handful of potential drugs. Even fewer of these candidate drugs are found to be effective at treating a disease. The drug must then pass strict safety standards in several series of clinical trials. According to the Pharmaceutical Research and Manufacturers of America's 2006 Pharmaceutical Industry Profile, developing a new drug and bringing it to the market takes up to 10 to 15 years and on average costs $800 million. ray

The FDA has also become more strict in the approval process. In 2007, the FDA approved 19 new drugs, the lowest number since 1983.[2]

Generic drugs: stiff competition

For a detailed discussion of brand name vs generic medication, see also Brand name vs Generic medications.

Due to Food and Drug Administration (FDA) regulations, pharmaceutical patents last 17 years, during which a pharmaceutical company has an exclusive right to manufacture a particular drug. After the patent expires, generic versions of the product can be produced and sold by competitors. Generic medication is cheaper to produce (due to the substantially lower research and development costs) than brand medication, and the lower cost is often a strong incentive for consumers to choose generics over branded drugs. In addition, the presence of a generic alternative may force a decrease in the brand name medication's price, through increased competition.

The generics industry itself is also facing the threat of cheaper competition. With the development of advanced drug manufacturing facilities in countries such as China, generics will likely undergo even further price cuts. China is already the world's largest supplier of raw materials for drug manufacture, but has not produced significant amounts of finished drugs for export. Last year, the FDA approved the first Chinese generic, a copy of the AIDS drug nevirapine, and another ten other Chinese companies are expected to come out with generics this year. [3]

Political pressures: pricing/licensing

Pharmaceutical companies face constant pressure from governments and activist organizations to increase access by either lowering prices substantially or granting generic licenses. Although these policies would increase the volume of sales, there would be a significant impact on total profits. However, if price controls or granting generic licenses occur, then companies will be less likely to invest money and research into new and unique medications. If this intellectual piracy occurs, less investment will occur.

Dependence on health insurance

Changes in health care coverage may impact drug sales. If an insurance program changes its policies and removes coverage for a certain treatment, sales of related drugs are likely to decrease. In general, insurance programs are more likely to cover essential expenses, such as heart disease medication, and less likely to cover nonessential expenses, such as cosmetic surgery.

Litigation risk

Pharmaceuticals can face significant liabilities if a medication is later found to be defective or produce adverse reactions. Even though such adverse reactions are previously unknown and impossible to predict, damages claimed in such lawsuits are usually substantial. Depending on jurisdiction, the legal system may limit allowable damages.

Future Growth Strategies

Drug development costs have increased significantly in the past decade due to increased FDA regulations and the desire for long term testing. The total cost and time to market for new drugs can be in the hundreds of millions of dollars and up to a decade, respectively. In addition, competition with generic drugs in emerging markets such as China and India have put pressure on drug companies' bottom lines. Despite these factors, drug companies do not prioritize cost cutting in the near future as much as other strategies for continued growth. In a recent survey of major executives at 15 large and medium drug companies, increased investment into R&D ranked first as a priority for the future, having been cited by 66% of the survey group. Cost cutting tied with expanding into new markets, as well as restructuring marketing in drawing 40% of the group (each executive was given two votes). [4]

Market Share by Region

Worldwide pharmaceutical sales increased by 8% in 2006 to £328 billion. The U.S. dominates the global demand for pharmaceutical drugs based on dollar amounts, accounting for nearly half of all sales.

Pharmaceuticals World Market Share by Region (2006) [5]

Value ($bn)* % of Total Growth vs. 2005**
USA 268.3 44% 9%
Europe 171.7 28% 6%
France 32.6 5% 4%
Germany 30.7 5% 3%
UK 20.0 3% 3%
Italy 19.4 3% 7%
Japan 57.9 10% -3%
Asia Pacific 43.1 7% 14%
Latin America 29.4 5% 21%
Middle East, Africa 20.9 3% 13%
Canada 15.4 3% 19%
Total 606.6 100% 8%

Note: *Based on an average 2006 £/$ exchange rate of 1.85 [6]

Note: **Based on £ figures from 2005; does not account for exchange rate difference between 2005 and 2006

Major Drug Manufacturers

While there are a great number of smaller publicly traded drug companies, the top firms represent the majority of the market. The following companies are each active in multiple therapeutic areas, whereas smaller firms generally specialize in a very specific product market.


Pharmaceutical and Biotech Industry — Competitive Operating Metrics (2007)

 

Johnson & Johnson (JNJ)

Pfizer (PFE)

Novartis (NVS)

Abbott Laboratories (ABT)

Merck (MRK)

Wyeth (WYE)

Bristol-Meyers Squibb (BMY)

Eli Lilly (LLY)

Amgen (AMGN)

Schering-Plough (SGP)

Boston Scientific (BSX)

Biogen Idec (BIIB)

Revenue (in billions of USD)

Total Revenue

$61.10

$48.42

$38.95

$25.91

$24.20

$22.40

$19.35

$18.63

$14.77

$12.69

$8.36

$3.17

Gross Profit

$43.34

$37.18

$27.04

$14.49

$18.06

$16.09

$13.13

$14.38

$12.22

$8.29

$6.02

$2.84

Revenue Growth from 2006

14.57%

0.10%

10.94%

15.30%

6.90%

10.07%

12.12%

18.75%

3.53%

19.78%

6.85%

18.21%

Income

Net Income

$10.58

$8.14

$11.95

$3.61

$3.28

$4.62

$2.17

$2.95

$3.17

-$1.47

-$0.50

$0.64

Net Profit Margin

17.31%

17.05%

16.79%

13.92%

13.54%

20.61%

14.12%

15.85%

21.43%

-11.61%

-5.92%

20.12%

Operating Income

$13.28

$9.28

$6.78

$4.58

$3.37

$6.46

$3.53

$3.88

$3.98

-$1.22

-$0.01

$0.78

Return on Average Equity

25.60%

12.06%

14.43%

22.66%

18.33%

28.09%

19.15%

23.96%

17.19%

-22.17%

-3.26%

10.05%

Other

Employees

119,200

86,600

98,200

68,000

59,800

50,527

42,000

40,600

17,500

55,000

27,500

4,300


Top Pharmaceutical Categories

Pharmaceuticals World Market of Top 5 Therapeutic Classes (2006) [7]

Value ($bn)* % of Total Growth vs. 2005**
Cardiovascular 100.8 17% 7%
Central nervous system 99.9 16% 8%
Alimentary tract and metabolic 73.6 12% 9%
Anti-infectives (bacterial,viral and fungal) excluding vaccines 61.4 10% 3%
Respiratory 40.1 7% 6%

Note: *Based on an average 2006 £/$ exchange rate of 1.85 [8]

Note: **Based on £ figures from 2005; does not account for exchange rate difference between 2005 and 2006

References

  1. Cowen and Company. Therapeutic Categories Outlook. March 2008.
  2. What's Ailing the Pharmaceutical Sector?.
  3. http://www.reuters.com/article/healthNews/idUSL1312745520080513?feedType=nl&feedName=ushealth1100
  4. Pharmalot. "Pharma Execs: Cost Cutting Is Not A Top Priority." 12 November 2008.
  5. GlaxoSmithKline 2006 20-F Filing, p. 26
  6. GlaxoSmithKline 2006 20-F Filing, p. 94
  7. GlaxoSmithKline 2006 20-F Filing, p. 26
  8. GlaxoSmithKline 2006 20-F Filing, p. 94


Top Ten/Twenty Best Selling Drugs 2009 http://knol.google.com/k/top-ten-twenty-best-selling-drugs-2009#

M&A Biotechnology http://knol.google.com/k/m-a-biotechnology#

http://knol.google.com/k/biotechnology-market-review-top-ten-biologics-2009#

Monoclonal Antibody Market 2009 http://knol.google.com/k/-/monoclonal-antibody-market-2009/3fy5eowy8suq3/86#

http://knol.google.com/k/new-drug-approvals-usa-fda-2009#

http://knol.google.com/k/new-drug-approvals-europe-ema-2009#

Vaccine Market 2009 http://knol.google.com/k/-/vaccine-market-2009/3fy5eowy8suq3/104#

http://knol.google.com/k/influenza-antivirals-market-2009#

Global Monoclonal Antibodies Market Review 2008 (World Top Ten mAbs) http://knol.google.com/k/global-monoclonal-antibodies-market-review-2008-world-top-ten-mabs#

M&A Review: Pharmaceutical & Biotechnology Industry http://knol.google.com/k/m-a-review-pharmaceutical-biotechnology-industry#

Global Vaccine Market Review 2008 (World Top Ten Vaccines) http://knol.google.com/k/global-vaccine-market-review-2008-world-top-ten-vaccines#

Global Pharmaceutical Market Review & World Top Ten/Twenty Drugs 2008 http://knol.google.com/k/global-pharmaceutical-market-review-world-top-ten-twenty-drugs-2008#

http://knol.google.com/k/global-market-intelligence-overview-monograph-2009#

http://knol.google.com/k/global-cardiovascular-market-review-2008-world-top-ten-cv-drugs#

http://knol.google.com/k/global-cancer-market-review-2008-world-top-ten-cancer-drugs#

http://knol.google.com/k/global-brain-drugs-market-review-2008-world-top-ten-cns-drugs#

http://knol.google.com/k/global-arthritis-market-review-2008-world-top-ten-ra-drugs#

http://knol.google.com/k/billion-dollar-generics-global-generic-market-review-2009#

http://knol.google.com/k/global-angiotensin-ii-receptor-antagonists-market-review-2008#

http://knol.google.com/k/global-antiviral-antibiotics-market-review-2008-world-top-ten-antimicrobial#

http://knol.google.com/k/global-diabetes-market-review-2008-world-top-ten-diabetes-drugs#

http://knol.google.com/k/global-respiratory-market-review-world-top-ten-respiratory-drugs-2008#

http://knol.google.com/k/global-pharmaceutical-market-intelligence-monograph#



Ipilimumab (BMS) Review: A Cancer Breakthrough? http://knol.google.com/k/-/ipilimumab-bms-review-a-cancer/3fy5eowy8suq3/107#

Denosumab (Prolia, Amgen) FDA Review & Approval http://knol.google.com/k/-/denosumab-prolia-amgen-fda-review/3fy5eowy8suq3/60#

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki